The regulatory clinical trial has commenced for “MediReg”®, an original domestically developed biologic drug based on the secretome of human mesenchymal stromal cells

Throughout life, the cellular components of tissues and organs require timely renewal and repair following significant damage. This function is carried out by stem cells, which in adult organisms are regulated by a specialized microenvironment known as the stem cell niche. Dysfunction of the niche can lead to loss of tissue integrity and impaired function. However, it has been demonstrated that the stem cell niche is capable of partial recovery. A significant contribution to this process is made by multipotent mesenchymal stem/stromal cells (MSCs), which are found in various tissue-specific stem cell niches, where they participate in maintaining and repairing damaged niches, presumably through the secretion of a wide range of factors collectively referred to as the secretome, which are involved in regulating tissue repair and regeneration. The use of the cell secretome, particularly that of MSCs, as regenerative medicine products underlies an emerging field of cell therapy known as “cell-free cell therapy”.

Recently, the first regulatory clinical trial of an original biological drug, “MediReg”®, based on the secretome of human MSCs was initiated in the Russian Federation. Developed and manufactured at Lomonosov Moscow State University, this drug is intended to treat severe impairments of spermatogenesis by stimulating the recovery of the damaged spermatogonial stem cell niche. In this brief communication, using “MediReg”® as an example, we discuss the key aspects of the development and preclinical studies of biological drugs based on the secretome of human MSCs, as well as the prospects for their translation into clinical practice.

1. Scadden DT. Nice Neighborhood: Emerging Concepts of the Stem Cell Niche. Cell. 2014;157:41–50.

2. Hicks MR, Pyle AD. The emergence of the stem cell niche. Trends Cell Biol. 2023;33(2): 112–123.

3. Sagaradze GD, Basalova NA, Efimenko AY, Tkachuk VA. Mesenchymal Stromal Cells as Critical Contributors to Tissue Regeneration. Front Сell Dev Biol. 2020;8:576176.

4. Bormann D, Gugerell A, Ankersmit HJ, Mildner M. Therapeutic Application of Cell Secretomes in Cutaneous Wound Healing. J Invest Dermatol. 2023;143(6):893–912.

5. Praveen K, Kandoi S, Misra R, et al. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1–9.

6. Sagaradze G., Grigorieva O., Nimiritsky P., Basalova N., Kalinina N., Akopyan Z., Efimenko A. Conditioned medium from human mesenchymal stromal cells: towards the clinical translation. International journal of molecular sciences. 2019;20(7):1–16.

7. Basalova N, Arbatskiy M, Popov V, et al. Mesenchymal stromal cells facilitate resolution of pulmonary fibrosis by miR-29c and miR-129 intercellular transfer. Experimental and Molecular Medicine. 2023;55:1399–1412.

8. Monakova A., Sagaradze G., Basalova N., Balabanyan V., Efimenko A. Novel Potency Assay for MSC Secretome-Based Treatment of Idiopathic Male Infertility Employed Leydig Cells and Revealed Vascular Endothelial Growth Factor as a Promising Potency Marker. International Journal of Molecular Science. 2022;23(16):9414.

9. Agarwal A., et al. Male infertility. The Lancet. 2021;397(10271):319–333.

10. Punab M., et al. Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts. Human Reproduction. 2017;32(1):18–31.

11. Chen G., et al. Medical management of male infertility: now and future. Current Opinion in Urology. 2023;33(1):10–15.

12. Diao L., et al. Roles of spermatogonial stem cells in spermatogenesis and fertility restoration. Frontiers in Endocrinology. 2022;13:895528.

13. Sagaradze GD, Monakova AO, Basalova NA, et al. Regenerative medicine for male infertility: a focus on stem cell niche injury models. Biomedical Journal. 2022;45(4):607–614.

14. Mohammed SS, Mansour MF, Salem NA. Therapeutic Effect of Stem Cells on Male Infertility in a Rat Model: Histological, Molecular, Biochemical, and Functional Study. Stem Cells International. 2021:8450721.

15. Tamadon A, et al. Induction of Spermatogenesis by Bone Marrow-derived Mesenchymal Stem Cells in Busulfan-induced Azoospermia in Hamsters. International Journal of Stem Cells. 2015;2(8):134–145.

16. Hajihoseini M, Vahdati A, Hosseini SE, et al. Induction of spermatogenesis after stem cell therapy of azoospermic guinea pigs. Veterinarski arhiv. 2017;87(3):333–350.

17. Sagaradze G, Basalova N, Kirpatovsky V, et al. A magic kick for regeneration: role of mesenchymal stromal cell secretome in spermatogonial stem cell niche recovery. Stem cell research & therapy. 2019;10(1):1–10.

18. Sagaradze GD, Basalova NA, Kirpatovsky VI, et al. Application of rat cryptorchidism model for the evaluation of mesenchymal stromal cell secretome regenerative potential. Biomedicine and Pharmacotherapy. 2019;109:1428–1436.

19. Монакова А.О., Сагарадзе Г.Д., Балабаньян В.Ю., Басалова Н.А., Матичина А.А., Матичин А.А. и др. Изучение безопасности оригинального препарата на основе секретома мезенхимных стромальных клеток при локальном введении в яички и при внутримышечном введении препарата крысам. Безопасность и риск фармакотерапии. 2024;12(1):99–116.

20. Монакова А.О., Балабаньян В.Ю., Вавилова В.А., Басалова Н.А., Попов В.С., Акопян Ж.А., Ефименко А.Ю. Изучение местной переносимости и фармакологической безопасности оригинального биологического лекарственного препарата МедиРег на основе секретома мезенхимных стромальных клеток при локальном введении в семенники кроликам. Безопасность и риск фармакотерапии. 2025;13(2):213–228.

21. Монакова А.О. и др. Роль макрофагов в реализации эффектов секретома мезенхимных стромальных клеток в нише сперматогониальной стволовой клетки. Современные технологии в медицине. 2025;17(2):37–47.